- Sputnik International, 1920
Russia
The latest news and stories from Russia. Stay tuned for updates and breaking news on defense, politics, economy and more.

RDIF: Sputnik V's Efficacy at 97.6% Based on Data Analysis of 3.8 Mln Vaccinated Russians

© REUTERS / OGNEN TEOFILOVSKIA nurse prepares a dose of Russia's Sputnik V coronavirus disease (COVID-19) vaccine at a sport centre, as the country starts mass inoculation campaign with the Russian vaccine donated by Serbia, in Skopje, North Macedonia April 5, 2021.
A nurse prepares a dose of Russia's Sputnik V coronavirus disease (COVID-19) vaccine at a sport centre, as the country starts mass inoculation campaign with the Russian vaccine donated by Serbia, in Skopje, North Macedonia April 5, 2021. - Sputnik International, 1920, 19.04.2021
Subscribe
MOSCOW (Sputnik) - The efficacy of the Russian coronavirus vaccine Sputnik V reached 97.6 percent, based on the analysis of data pertaining to post-vaccination infection percentage among vaccinated Russians, the Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) announced on Monday.
"The Sputnik V vaccine demonstrated an efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of Sputnik V", the statement says.

According to the data from 3.8 million Russians vaccinated with both components of Sputnik V from 5 December to 31 March, the infection rate starting from the 35th day from the date of the first injection was only 0.027 percent, compared to 1.1 percent incidence among the unvaccinated adult population, it says.

"The data and calculations of the vaccine’s efficacy will be published in a peer-reviewed medical journal in May", it says.

​Russia's Sputnik V vaccine is approved for use in 60 countries with a total population of about three billion people. The vaccine efficacy has been confirmed at 91.6 percent by the data published in the world's leading medical journal The Lancet.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала